

# MIPLYFFA (arimoclomol)

#### **Pre - PA Allowance**

None

## **Prior-Approval Requirements**

Age 2 years of age or older

#### Diagnosis

Patient must have the following:

Niemann-Pick disease type C (NPC)

AND ALL the following:

- 1. NPC diagnosis confirmed by genetic testing identifying disease causing variants in the NPC1 or NPC2 genes
- 2. Miplyffa is being used for the neurological manifestations of NPC
- 3. Used in combination with miglustat
- 4. Prescriber agrees to monitor for hypersensitivity reactions and increased creatinine

### **Prior - Approval Limits**

**Quantity** 372 mg per day

**Duration** 2 years

## Prior – Approval Renewal Requirements

Age 2 years of age or older

#### Diagnosis

Patient must have the following:

Niemann-Pick disease type C (NPC)

#### AND ALL of the following:

- 1. Neurological manifestations have improved or stabilized
- 2. Used in combination with miglustat
- 3. Prescriber agrees to monitor for hypersensitivity reactions and increased creatinine



#### MIPLYFFA (arimoclomol)

## Prior - Approval Renewal Limits

Same as above